September 16, 2024

Table S14 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

GSEA analysis of genes with significantly lower H3K27ac at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.

Me gusta

Guardar

Cite This Study

Venneti et al. (Mon,) studied this question.

synapsesocial.com/papers/68e586b5b6db6435875232fe https://doi.org/https://doi.org/10.1158/2159-8290.27026258

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S14 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
2Table S13 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
3Table S13 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
4Table S9 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024
5Table S9 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways2024

Me gusta

Guardar